Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Goldstone

Showing results (171-180 of 311) with videos related to

Pageof 32
Sort By:
British Journal of Haematology|July 26, 2002
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trialAlan K Burnett, Keith Wheatley, Anthony H Goldstone, et al.
Bone Marrow Transplantation|July 6, 2004
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantationI Avivi, S Chakrabarti, P Kottaridis, et al.
Blood|October 24, 2002
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationStephen P Robinson, Anthony H Goldstone, Stephen Mackinnon, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Leukemia & Lymphoma|July 27, 2016
Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential ThrombocythaemiaF J Giles, C C Anderson, I R Grant, et al.
Lancet (London, England)|July 26, 1980
Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemiaH G Prentice, J F Smyth, K Ganeshaguru, et al.
Leukemia & Lymphoma|May 18, 2012
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experienceJonathan Sive, Kirit M Ardeshna, Simon Cheesman, et al.
Lancet (London, England)|April 24, 1993
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialD C Linch, D Winfield, A H Goldstone, et al.
Blood|August 25, 2001
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialD Grimwade, H Walker, G Harrison, et al.
British Journal of Haematology|November 1, 1986
Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemiaA H Goldstone, C C Anderson, D C Linch, et al.
Pageof 32

Showing results (171-180 of 311) with videos related to

Sort By:
Pageof 32
British Journal of Haematology|July 26, 2002
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trialAlan K Burnett, Keith Wheatley, Anthony H Goldstone, et al.
Bone Marrow Transplantation|July 6, 2004
Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantationI Avivi, S Chakrabarti, P Kottaridis, et al.
Blood|October 24, 2002
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow TransplantationStephen P Robinson, Anthony H Goldstone, Stephen Mackinnon, et al.
Blood|March 8, 2003
Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsEmma C Morris, Peppy Rebello, Kirsty J Thomson, et al.
Leukemia & Lymphoma|July 27, 2016
Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential ThrombocythaemiaF J Giles, C C Anderson, I R Grant, et al.
Lancet (London, England)|July 26, 1980
Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemiaH G Prentice, J F Smyth, K Ganeshaguru, et al.
Leukemia & Lymphoma|May 18, 2012
Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experienceJonathan Sive, Kirit M Ardeshna, Simon Cheesman, et al.
Lancet (London, England)|April 24, 1993
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialD C Linch, D Winfield, A H Goldstone, et al.
Blood|August 25, 2001
The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trialD Grimwade, H Walker, G Harrison, et al.
British Journal of Haematology|November 1, 1986
Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemiaA H Goldstone, C C Anderson, D C Linch, et al.
Pageof 32